glp 1 pharmacology glp-1_ra_pharmacology [TUSOM GLP-1, glucagon, and GIP mechanisms

The tail that wags the dog: how the disordered C-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein

Understanding the functional effects of different mutations is critical for personalized treatment and genetic counseling, but understanding these effects is challenging because of the rarity of mutations in many individuals

outcomes vary

Tesamorelin safety: documented The Egrifta prescribing information reports injection site reactions (redness, pain, swelling) in a meaningful proportion of trial participants

Oral administration is more likely to produce a good response when compared to the use of topical applications

The Lancet Diabetes and Endocrinology 7(10):776785